Farmacia Hospitalaria xxx (xxxx) 1-7



Farmacia HOSPITALARIA Organo oficial de expresión científica de la Sociedad Española de Farmacia Hospitalaria



www.elsevier.es/farmaciahospitalaria

Original article

[Translated article] Knowledge, perception and predisposition to implement the MAPEX strategy in hospital pharmacy residents in Spain. FIRMAPEX project

María Alfonsín Lara^{a,b}, Vera Áreas del Águila^c, Enrique Contreras Macías^{d,*}, Almudena Mancebo González^e, Beatriz Martínez Castro^f, Covadonga Pérez Menéndez-Conde^g, Patricia Sanmartín Fenollera^h and Ramón Morillo-Verdugoⁱ

- ^a Servicio de Farmacia, Hospital Álvaro Cunqueiro, Vigo, Spain
- ^b Sociedad Española de Farmacia Hospitalaria, Vigo, Spain
- ^c Servicio de Farmacia, Hospital General Universitario de Ciudad Real, Ciudad Real, Spain
- ^d Servicio de Farmacia, Hospital San Juan de Dios, Sevilla, Spain
- ^e Servicio de Farmacia, Hospital Clínico Universitario Arrixaca, Murcia, Spain
- f Servicio de Farmacia, Hospital Universitari Arnau de Vilanova, Lleida, Spain
- g Servicio de Farmacia, Hospital Ramón y Cajal, Madrid, Spain
- ^h Servicio Farmacia, Hospital Universitario Fundación Alcorcón, Madrid, Spain
- ⁱ Servicio de Farmacia, Hospital de Valme, Sevilla, Spain

ARTICLE INFO

Article history: Received 26 January 2025 Accepted 15 April 2025 Available online xxxx

Keywords: Pharmaceutical care Hospital pharmacy Outpatient Pharmacy intership

ABSTRACT

Objective: To assess the level of knowledge, perception, and willingness of hospital pharmacy residents in Spain to implement the initiatives of the MAPEX project (Strategic Map for Outpatient Pharmaceutical Care) by the Spanish Society of Hospital Pharmacy in the future, as well as to analyze the influence of outpatient pharmacy rotations on these aspects.

Methods: A four-phase study was conducted: information review and analysis, questionnaire design, survey administration, and final report development. A questionnaire was designed to assess knowledge, perception, and application of MAPEX, as well as experience in outpatient pharmacy rotations. Factorial and bivariate analyses were performed to evaluate the questionnaire structure and identify associations between variables.

Results: A total of 143 residents participated. Of these, 78.3% had completed an outpatient pharmacy rotation, which was significantly associated with greater knowledge (p=0.02) and application (p=0.01) of MAPEX. However, only 15.4% had a high level of knowledge, and 12.6% frequently applied the Capacity-Motivation-Opportunity (CMO) methodology. Although 71.3% positively valued motivational interviewing, only 28% used it frequently. Willingness to implement MAPEX was high (73.4%), reaching 100% among those with a high level of knowledge about the project (p=0.04). Factor analysis identified six factors explaining 66.8% of the total variance

Conclusions: Hospital pharmacy residents demonstrated a positive perception and a high willingness to implement MAPEX, highlighting the need for its structured integration into specialized training. Outpatient pharmacy rotations significantly improve knowledge and application of the CMO methodology, emphasizing their importance in pharmaceutical care training.

© 2025 The Author(s). Published by Elsevier España, S.L.U. on behalf of Sociedad Española de Farmacia Hospitalaria (S.E.F.H). This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

DOI of original article: https://doi.org/10.1016/j.farma.2025.04.007.

E-mail address: enriquecm92@gmail.com (E. Contreras Macías).

https://doi.org/10.1016/j.farma.2025.10.001

1130-6343/© 2025 The Author(s). Published by Elsevier España, S.L.U. on behalf of Sociedad Española de Farmacia Hospitalaria (S.E.F.H). This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Please cite this article as: Alfonsín Lara M, et al.. [Translated article] Knowledge, perception and predisposition to implement the MAPEX strategy in hospital pharmacy residents in Spain. FIRMAPEX project. Farmacia Hospitalaria. 2025. https://doi.org/10.1016/j.farma.2025.10.001

^{*} Corresponding author.

M. Alfonsín Lara, V. Áreas del Águila, E. Contreras Macías et al.

Farmacia Hospitalaria xxx (xxxx) 1-7

Conocimiento, percepción y predisposición a implantar la estrategia MAPEX en residentes de farmacia hospitalaria en España. Proyecto FIRMAPEX

RESUMEN

Palabras clave: Atención farmacéutica Farmacia hospitalaria Paciente externo Residencia Objetivo: evaluar el grado de conocimiento, percepción y predisposición de los residentes de Farmacia Hospitalaria en España para implementar, en el futuro, las iniciativas del proyecto MAPEX (Mapa Estratégico para la Atención Farmacéutica al Paciente Externo) de la Sociedad Española de Farmacia Hospitalaria, así como analizar la influencia de la rotación en consultas externas en estos aspectos.

Métodos: estudio en 4 fases: revisión y análisis de información, diseño del cuestionario, realización de la encuesta y elaboración del informe final. Se diseñó un cuestionario para evaluar el conocimiento, percepción y aplicación de MAPEX, además de la experiencia en rotaciones por consultas externas. Se emplearon análisis factoriales y bivariantes para evaluar la estructura del cuestionario y las asociaciones entre variables.

Resultados: participaron 143 residentes. El 78,3% había realizado la rotación en consultas externas, lo que se asoció con un mayor conocimiento (p=0,02) y aplicación (p=0,01) de MAPEX. Solo el 15,4% tenía un conocimiento alto, y el 12,6% aplicaba frecuentemente la metodología Capacidad-Motivación-Oportunidad (CMO). Aunque el 71,3% valoró positivamente la entrevista motivacional, solo el 28% la empleaba con frecuencia. La predisposición a implementar MAPEX fue alta (73,4%), alcanzando el 100% entre quienes tenían un conocimiento elevado del proyecto (p=0,04). El análisis factorial identificó 6 factores que explicaron el 66,8% de la variancia total.

Conclusiones: los residentes muestran una percepción positiva y alta predisposición para aplicar MAPEX, destacando la necesidad de su integración en la formación especializada. La rotación en consultas externas mejora significativamente el conocimiento y la aplicación de la metodología CMO, resaltando su importancia en la capacitación en atención farmacéutica.

© 2025 Los Autores. Publicado por Elsevier España, S.L.U. en nombre de Sociedad Española de Farmacia Hospitalaria (S.E.F.H). Este es un artículo Open Access bajo la licencia CC BY-NC-ND (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Introduction

The management of chronic diseases emerges as a major challenge in global healthcare systems due to the exponential growth of these diseases and their impact on quality of life. This situation has created a need to reconsider healthcare strategies, health policies, and therapeutic approaches in order to address this challenge comprehensively and sustainably. A thorough understanding of the complexities inherent in healthcare systems, organizational structures, and public health initiatives is essential to ensure an efficient use of resources and enhanced quality of life. A variety of entities are striving to find new strategies that address these challenges from a comprehensive and sustainable approach.

In the context of Hospital Pharmacy (HP), the steady increase in the number of patients attended in outpatient clinics (OCs), together with resource scarcity, hindered the integration of hospital pharmacists in multidisciplinary teams, resulting in significant variability in patient care. This situation drove the Spanish Society of Hospital Pharmacy (SEFH) to launch a collaborative project to better address these issues. In 2014, the SEFH developed the Outpatient Pharmaceutical Care Plan (MAPEX), based on three basic principles: multidisciplinary and multidimensional care, excellence in knowledge, and evaluation of results.

Since then, and following the I Consensus Conference held in 2016, a range of initiatives have been developed to address current challenges.^{5–7} One of the most remarkable achievements was the redefinition of pharmaceutical care (PC)⁸ and the creation of the "CMO Model" after Capacity, Motivation and Opportunity. This model met the three major needs identified: personalized care, care based on pharmacotherapeutic goals, and seamless follow-up.⁹ In line with our commitment to quality of care, a pioneer certification standard, the Q-PEX initiative, ¹⁰ was developed in 2019.

A comparative analysis of the impact of the project on PC revealed significant improvements both at the national and regional levels. ^{11,12} The II Consensus Conference was held in 2013 to establish priority initiatives to be developed in the 2024–2027 period. One of the initiatives included was "Establishing mechanisms to disseminate MAPEX contents in relation to pharmaceutical care in undergraduate and resident training plans". It is worth mentioning that the national HP education plan was

approved by the National Specialty Committee as far as in 1999.¹³ Throughout the project, a variety of education and training initiatives have been implemented to disseminate and raise awareness of the activities developed. However, to date, the level of awareness that future pharmacists have of these initiatives and their level of implementation at present and in the future is unknown.

The primary objective of this study is to identify the level of knowledge, perception and willingness of HP residents in Spain to implement MAPEX initiatives in the future. A secondary goal is to determine the structural validity of the questionnaire designed for the purposes of this study.

Methods

The study was carried out in four phases extending from January to December 2024. The first phase of the project involved organizing the work, analyzing developments and the context, selecting experts, and planning (Phase 1). The second phase entailed drafting the questionnaire (Phase 2), conducting the survey (Phase 3), and finally, preparing the final report and disseminating results (Phase 4).

In Phase 1, an evaluation of project progress between 2015 and 2023 was performed. To this end, a research group was created including HP specialists experienced in PC and MAPEX from different HPs across Spain, along with members of the SEFH Mentorship Working Group and the SEFH representative of residents. This group reviewed and validated the goals, scope, expectations and methods used to design the questionnaire. Additionally, the research group took part in other actions, such as reviewing literature, drafting questionnaire proposals, reaching consensus, reviewing drafts, disseminating the questionnaire and validating the final report.

Phase 2 involved a review and evaluation of relevant literature. To this end, the following MeSH keywords were identified: HP; PC; telepharmacy; training; multidisciplinary integration; and questionnaires. Other useful non-MeSH keywords were added in the literature search for their relation with the MAPEX project. The literature search was restricted to papers published in the last eight years, either in Spanish or English.

M. Alfonsín Lara, V. Áreas del Águila, E. Contreras Macías et al.

Farmacia Hospitalaria xxx (xxxx) 1-7

Subsequently, an analysis was performed of published questionnaires to gather opinions and experiences with HP initiatives at the national substitutional levels. Additionally, the questionnaires identified were evaluated to determine their validity and viability in our context. Finally, items of interest were grouped into dimensions to characterize the questionnaire, and the final version was established.

Once all the evidence had been gathered, a preliminary questionnaire was drafted, and revisions were made to adjust its semantics. To such end, first, the criteria and items to be included were defined according to the analysis of the literature and in line with previous MAPEX initiatives.

The research group reviewed the preliminary proposal to adjust items, incorporate modifications and develop questionnaire methodology, as well as to reach consensus on these issues and establish a schedule.

A total of 24 questions were defined and classified into four blocks, namely: descriptive questions, MAPEX initiatives, training, and future. Numeric answer options were included. Responses were rated on a 10-point Likert scale and grouped based on their rating: low = 1-4, moderate = 5-7, and high >7. In addition, demographic questions were included, and participants were interrogated about previous rotations in an outpatient HP department. An introduction to the questionnaire was also included to present the project and explain the goals of the survey. Information was included about the time required to complete the questionnaire and its anonymity.

The online questionnaire was disseminated via Google Forms®, which was also used to collect and process information anonymously.

Prior to the final distribution of the questionnaire, a pilot test was carried out in a small group of residents. The purpose was to evaluate the clarity, intelligibility and functionality of questionnaire items, along with identifying potential phrasing errors or ambiguities. A minimum of 20 participants were selected from the centers of the research group. According to the literature, this sample size is adequate for identifying systematic errors in measurement tools. This approach ensures process efficiency and prioritizes error identification, without necessitating a representative statistical analysis at this stage.

Participants anonymously completed the questionnaire on the online platform, mimicking real-world conditions. The pilot group included residents at different levels of training to identify issues relevant to the target population.

Qualitative analysis of pilot-phase feedback led to item rewording and format adjustments before the final version was disseminated. As a result, a clear, intelligible questionnaire appropriate for the primary assessment goal was established.

Eventually, the content of the final questionnaire version was determined, with "How would you assess the level of training provided to pharmacy residents in the methodology and implementation of MAPEX initiatives in your setting?" having been established as the main research question.

The research group agreed to include HP residents of all years of specialty training in the study population, except for first-year residents. Sample size was calculated using Spanish Ministry of Health data regarding HP residency vacancies available on its website and pharmacy practice (PR)-related documents. To ensure sample representativeness, the following conditions were established: an expected proportion of 50% (p=0.5) to maximize variability, a 95% confidence interval, and 5% sampling error.

In phase 3, the data collection period started in October 2024. The online questionnaire was distributed through the SEFH official channels, reaching all eligible candidates. A transparent, non-competitive recruitment process was conducted at hospitals across all levels of care in all autonomous communities in Spain where PH residency plans were available. To ensure an adequate sample size, the questionnaire could not be submitted unless all questions were answered.

In phase 4, a descriptive analysis of the baseline characteristics of participants was performed. Categorical variables were expressed as

absolute frequencies and percentages. Bivariate Chi-square analyses were conducted to examine associations between outpatient rotation participation, questionnaire responses, and MAPEX project knowledge. Assigning a high score to the first two questions indicated a high level of understanding of MAPEX.

For the secondary objective, the structural validity of the questionnaire was evaluated by principal component factor analysis with varimax rotation. The suitability of the data for factor analysis was assessed via the Kaiser-Meyer-Olkin (KMO) measure and Bartlett's Test of Sphericity. Factors with eigenvalues > 1 were retained. A scree plot was used to determine the optimal number of factors. Factor loadings > 0.6 were indicated as representativeness. All analyses were performed using the SPSS version 26 software package (IBM Corp., Armonk, NY, USA).

Results

A total of 143 PRs completed the survey. Most participants were female (71.3%), of whom 86% were younger than 30. The geographic distribution was representative of all autonomous communities, which guaranteed sample diversity. As many as 78.3% of respondents had already completed their outpatient pharmacy rotation period (Table 1). In total, 15.4% and 42.7% of participants had a high and a low level of understanding of the MAPEX project, respectively. MAPEX knowledge differed significantly between participants who had completed the outpatient HP rotation and those who had not (p=0.02). Thus, the residents having completed the outpatient HP rotation were more familiarized with the MAPEX project (17% vs. 3.8%) (Table 2).

With respect to knowledge and adoption of the CMO methodology, only 12.6% of participants reported using it frequently, with participants having completed rotation showing a higher level of familiarity with this method (p=0.01). The use of CMO was more frequent among participants with a high understanding of MAPEX (40.0% vs. 9.4%, p<0.01). Participants considered motivational interviewing to be highly relevant (71.3%), albeit only 28.0% used it frequently. Residents strongly familiar with MAPEX were more likely to use motivational interviewing (60.0% vs. 24.2%, p<0.01) (Table 3).

Finally, in relation to participants' perception and willingness to implement MAPEX in the future, 73.4% showed a high willingness, reaching 100% among participants with a high level of knowledge (p = 0.04) (Table 4).

On another note, the exploratory factor analysis conducted to explore the structural validity of the questionnaire identified a consistent

Baseline characteristics of study participants.

	Participants ($n = 143$)
Women; n (%)	102 (71.3)
Age < 30 years	123 (86)
Has completed outpatient pharmacy rotation	94 (78.3)
Autonomous community n (%)	
Andalusia	23 (16.1)
Aragon	4 (2.8)
Asturias	4 (2.8)
Balearic Islands	1 (0.7)
Canary Islands	4 (2.8)
Cantabria	2 (1.4)
Castilla La Mancha	9 (6.3)
Castilla y León	4 (2.8)
Catalonia	14 (9.8)
Extremadura	3 (2.1)
Galicia	5 (3.5)
La Rioja	2 (1.4)
Madrid	25 (17.5)
Murcia	12 (8.4)
Navarre	5 (3.5)
Basque Country	10 (7)
Valencian Community	16 (11.2)

M. Alfonsín Lara, V. Áreas del Águila, E. Contreras Macías et al.

Farmacia Hospitalaria xxx (xxxx) 1–7

Table 2 Questionnaire Responses.

		Total (<i>N</i> = 143) <i>N</i> (%)
What is your level of knowledge regarding the main	Low	61 (42.7)
objectives of the MAPEX project?	Moderate	60 (42.0)
	High	22 (15.4)
How familiar are you with the initiatives developed	Low	59 (41.3)
within the MAPEX project over the past 10 years	Moderate	62 (43.4)
(e.g., QPEX. CMO, integration, telepharmacy)?	High	22 (15.4)
How do you perceive the integration of hospital	Low Moderate	21 (14.7)
pharmacists into multidisciplinary teams according to MAPEX recommendations?	High	55 (38.5) 67 (46.9)
What is your opinion on the potential of MAPEX	Low	13 (9.1)
initiatives to improve multidisciplinary	Moderate	60 (42.0)
collaboration in your workplace	High	70 (49.0)
Are you familiar with the pharmaceutical care	Low	50 (35.0)
methodology developed in MAPEX, the CMO model	Moderate	55 (38.5)
(Capacility-Motivation-Opportunity)?	High	38 (26.6)
Do you apply the pharmaceutical care methodology	Low	72 (50.3)
developed in MAPEX -the CMO model- in the	Moderate	53 (37.1)
management of outpatients in your setting?	High	18 (12.6)
How would you rate the importance of adapting	Low	9 (6.3)
MAPEX pharmaceutical care recommendations to	Moderate	50 (35.0)
the different patient profiles treated in outpatient clinics?	High	84 (58.7)
Do you consider that the pharmaceutical care	Low	14 (9.8)
recommendations from MAPEX initiatives	Moderate	70 (49.0)
adequately cover all diseases managed in outpatient clinics?	High	59 (41.3)
What is your opinion on the need to provide	Low	2 (1.4)
personalized pharmaceutical care using patient	Moderate	32 (22.4)
stratification?	High	109 (76.2)
Do you consider motivational interviewing to be a key	Low	2 (1.4)
tool for communication with outpatients?	Moderate	39 (27.3)
	High	102 (71.3)
Do you use motivational interviewing in your	Low	38 (26.6)
communication with outpatients in hospital	Moderate	65 (45.5)
pharmacy practice? What is your perception of the usefulness of adapting	High Low	40 (28.0) 9 (6.3)
MAPEX initiatives to different patient profiles in	Moderate	69 (48.3)
order to improve health outcomes?	High	65 (45.5)
In your opinion, how challenging is the	Low	61 (42.7)
implementation of MAPEX initiatives in your	Moderate	66 (46.2)
current workplace?	High	16 (11.2)
What is your opinion on the relevance of QPEX	Low	10 (7.0)
certification for improving the quality of	Moderate	71 (49.7)
pharmaceutical care in hospital pharmacy outpatient departments?	High	62 (43.4)
How confident do you feel in your ability to work	Low	37 (25.9)
according to the QPEX quality standards in your	Moderate	68 (47.6)
hospital?	High	38 (26.6)
Do you think that MAPEX has promoted the	Low	15 (10.5)
development of dual pharmaceutical care (in-	Moderate	62 (43.4)
person + telepharmacy)?	High	66 (46.2)
How familiar are you with the concept of	Low	29 (20.3)
telepharmacy and its areas of application as	Moderate	73 (51.0)
promoted through MAPEX initiatives?	High Low	41 (28.7)
How would you assess the level of training provided to		56 (39.2) 68 (47.6)
pharmacy residents (PRs) in the methodology and implementation of MAPEX initiatives in your setting?	Moderate High	68 (47.6) 19 (13.3)
setting? How much of a priority do you think it is to	Low	7 (4.9)
incorporate all the improvements developed within	Moderate	7 (4.9) 50 (35.0)
MAPEX into PR training?	High	86 (60.1)
What would be your willingness to implement MAPEX	Low	3 (2.1)
methodologies and initiatives in the future when	Moderate	35 (24.5)
working as a hospital pharmacist in outpatient care?	High	105 (73.4)
What would be your willingness to collaborate in and	Low	4 (2.8)
contribute to the development of future MAPEX	Moderate	42 (29.4)
projects?	High	97 (67.8)
How important do you think it is for the MAPEX	Low	3 (2.1)
project to remain active over the coming years for	Moderate	34 (23.8)
project to remain active over the coming years for		

Scale scores: low = 1-4, moderate = 5-7, high > 7.

Table 3Results of bivariate analyses based on outpatient HP rotation completion status.

		Have you completed outpatient pharmacy rotation?		
		No (n = 26)	Yes (n = 94)	p*
Question 1	Low	18 (69.2)	37 (39.34)	0.02
	Moderate	7 (26.9)	41 (43.6)	
	High	1 (3.8)	16 (17)	
Question 2	Low	18 (69.2)	34 (36.2)	0.01
	Moderate	7 (26.9)	44 (46.8)	
0	High	1 (3.8)	16 (17)	0.43
Question 3	Low Moderate	4 (15.4) 7 (26.9)	16 (17) 37 (39.4)	0.42
	High	15 (57.7)	41 (43.6)	
Question 4	Low	1 (3.8)	12 (12.8)	0.39
C	Moderate	13 (50)	39 (41.5)	
	High	12 (46.2)	43 (45.7)	
Question 5	Low	13 (50)	30 (31.9)	0.08
	Moderate	11 (42.3)	39 (41.5)	
	High	2 (7.7)	25 (26.6)	0.45
Question 6	Low	12 (46.2)	54 (57.4)	0.15
	Moderate High	10 (38.5)	35 (37.2) 5 (5.3)	
Question 7	Low	4 (15.3) 1 (3.8)	7 (7.4)	0.65
Question 7	Moderate	11 (42.3)	32 (34)	0.03
	High	14 (53.8)	55 (58.5)	
Question 8	Low	1 (3.8)	11 (11.7)	0.23
-	Moderate	17 (65.4)	45 (47.9)	
	High	8 (30.8)	38 (40.4)	
Question 9	Low	1 (3.8)	1 (1.1)	0.49
	Moderate	7 (26.9)	20 (21.3)	
0 .: 10	High	18 (69.2)	73 (77.7)	0.75
Question 10	Low	0 (0)	2 (2.1)	0.75
	Moderate High	7 (26.9)	26 (27.7)	
Question 11	Low	19 (73.1) 6 (23.1)	66 (70.2) 27 (28.7)	0.65
Question 11	Moderate	14 (53.8)	41 (43.6)	0.03
	High	6 (23.1)	26 (27.7)	
Question 12	Low	1 (3.8)	8 (8.5)	0.25
	Moderate	16 (61.5)	41 (43.6)	
	High	9 (34.6)	45 (47.9)	
Question 13	Low	4 (15.4)	51 (54.3)	< 0.0
	Moderate	21 (80.8)	32 (34)	
Ourantian 14	High	1 (3.8)	11 (11.7)	0.53
Question 14	Low Moderate	1 (3.8)	8 (8.5) 44 (46.8)	0.53
	High	15 (57.7) 10 (38.5)	42 (44.7)	
Question 15	Low	2 (7.7)	33 (35.1)	0.03
C	Moderate	16 (61.5)	41 (43.6)	
	High	8 (30.8)	20 (21.3)	
Question 16	Low	0 (0)	14 (14.9)	0.09
	Moderate	14 (53.8)	37 (39.4)	
	High	12 (46.2)	43 (45.7)	
Question 17	Low	8 (30.8)	18 (19.1)	0.24
	Moderate High	14 (53.8)	48 (51.1)	
Question 18	Low	4 (15.4) 7 (26.9)	28 (29.8) 44 (46.8)	0.02
Question to	Moderate	12 (46.2)	42 (44.7)	0.02
	High	7 (26.9)	8 (8.5)	
Question 19	Low	1 (3.8)	6 (6.4)	0.52
-	Moderate	11 (42.3)	29 (30.9)	
	High	14 (53.8)	59 (62.8)	
Question 20	Low	0 (0)	3 (3.2)	0.52
	Moderate	8 (30.8)	22 (23.4)	
	High	18 (69.2)	69 (73.4)	
Question 21	Low	0 (0)	4 (4.3)	0.56
	Moderate	8 (30.8)	27 (28.7)	
Question 22	High Low	18 (69.2)	63 (67)	0.63
Question 22	Moderate	0 (0) 7 (26.9)	3 (3.2) 22 (23.4)	0.03
	High	19 (73.1)	69 (73.4)	
		15 (75.1)	03 (73.4)	

^{*} p calculated by the Chi-square test or Fisher's exact test, as appropriate.

latent structure composed of six factors aggregately explaining 66.8% of the total variance in responses. The KMO sample suitability test yielded a value of 0.828, thus indicating an excellent partial correlation between

M. Alfonsín Lara, V. Áreas del Águila, E. Contreras Macías et al.

Farmacia Hospitalaria xxx (xxxx) 1–7

Table 4Results of bivariate analysis by level of knowledge about MAPEX.

Moderate High 45 (35.2) (35.2) (35.3) 8 (53.3) (60.4) High 12 (9.4) (30.4) 6 (40) Question 7 Low (9 (7) (30.0) 0.06 Moderate (48 (37.5) (31.3) 13 (86.7) 2 (13.3) High (10.9) (30.0) 0 (0) (0) (0.01 <0.01 Moderate (86 (53.1) (21.3)) 13 (86.7) 0 (0) (0) (0.26 Moderate (31 (24.2) (16.7) (16.7) 14 (93.3) 0 (0) (0) (0.24 Mustion 10 (10.0) (10.0) (10.0) (10.0) (10.0) (10.0) 2 (1.6) (10.0) (10.0) (10.0) (10.0) 0 (0.0) (0.0) (0.0) (0.0) Question 11 (10.0) (10.			Would you consider your level of knowledge of MAPEX to be high?		
Moderate 51 (39.8) 4 (26.7) Question 4 Low 12 (9.4) 11 (73.3) Question 4 Low 12 (9.4) 11 (73.3) Question 5 Low 50 (39.1) 0 (0) < 0.01			No $(n = 128)$	Yes (n = 15)	p^*
Question 4 Low 12 (94) 11 (73.3) 0.13 Moderate 57 (44.5) 3 (20) 0.13 Moderate 57 (44.5) 3 (20) 0.01 High 59 (46.1) 11 (73.3) 0.00 Question 5 Low 50 (39.1) 0 (0) <0.01	Question 3	Low	21 (16.4)	0 (0)	0.06
Question 4 Low Moderate High 12 (9.4) (9.1) (16.7) 1 (6.7) (3.3) Question 5 Low 50 (39.1) (9.0) (0.0) < 0.01 (6.7)					
Moderate		-			0.40
Question 5 High Moderate by 10 (38.1) 11 (73.3) 0.001 < 0.01 Question 6 Low 50 (38.1) 0 (00) < 0.01	Question 4				0.13
Question 5 Low Moderate 54 (42.2) (16.7) (6.7) (16.7)					
Moderate High 54 (42.2) 1 (6.7) High 24 (18.8) 14 (93.3) Question 6 Low 71 (55.5) 1 (6.7) < 0.01	Question 5				< 0.01
Question 6 High Low 71 (55.5) (1 (6.7) (0.01) (6.7) (0.01) (7.5) (1 (6.7) (0.01) (1 (6.7)	Question 5			, ,	\0.01
Question 6 Low Moderate 45 (35.2)			, ,		
Moderate High 45 (35.2) (35.2) (35.3) (37.4) High High 12 (9.4) (37.4) 6 (40) (40) (37.4) Question 7 Low 9 (7) (7) (0 (0) (0) (0.06) 0.06 Moderate High 71 (55.5) (31.3) (36.7) 2 (13.3) (37.3) High 71 (55.5) (31.3) (2 (13.3) (36.7) 2 (13.3) (36.7) Question 8 Low 14 (10.9) (0 (0) (0) (0.26) Moderate High 46 (35.9) (31.3) (36.7) 13 (86.7) Question 9 Low 2 (1.6) (0 (0) (0) (0.26) Moderate High 31 (24.2) (1 (6.7) (6.7) (16.7) High 95 (74.2) (14 (93.3) Question 10 Low 2 (1.6) (0 (0) (0) (0.24) Moderate High 38 (29.7) (1 (6.7) (6.7) (7.7) (7.7) (1.6) Moderate Se (66.1) (6.1) (6.40) (1.2) (1.6)	Question 6				< 0.01
Question 7 High Low 9 (7) 0 (0) 0.06 Moderate Migh 48 (37.5) 2 (13.3) 0.06 Question 8 Low 14 (10.9) 0 (0) <0.01	_	Moderate	45 (35.2)		
Question 8 Moderate High (7) (55.5) 13 (86.7) Question 8 Low (14 (10.9)) 0 (0) < 0.01		High			
Question 8 High Low 14 (10.9) (10.0) (0.0) (0.0) < 0.01 (0.0) (0.0) < 0.01 (0.0) (0.0) < 0.01 (0.0) (0.0) < 0.01 (0.0) (0.0) < 0.01 (0.0) (0.0) < 0.01 (0.0) (0.0) < 0.02 (0.0) (0.0) < 0.02 (0.0) (0.0) < 0.02 (0.0) (0.0) (0.0) < 0.02 (0.0) (0.0) (0.0) < 0.02 (0.0) (0.0) (0.0) (0.0) < 0.02 (0.0) (0.0) (0.0) (0.0) < 0.02 (0.0) (0.0) (0.0) (0.0) < 0.01 (0.0) (0.0) (0.0) (0.0) < 0.01 (0.0) (0.0) (0.0) (0.0) < 0.01 (0.0) (0.0) (0.0) (0.0) < 0.01 (0.0) (0.0) (0.0) (0.0) < 0.01 (0.0) (0.0) (0.0) (0.0) < 0.01 (0.0) (0.0) (0.0) (0.0) < 0.01 (0.0) (0.0) (0.0) (0.0) < 0.01 (0.0) (0.0) (0.0) (0.0) < 0.01 (0.0) (0.0) (0.0) (0.0) (0.0) < 0.01 (0.0) (0.0) (0.0) (0.0) (0.0) (0.0) < 0.01 (0.0) (Question 7	Low	9 (7)	0 (0)	0.06
Question 8 Low Moderate (as (53.1) (as (53.3)) 0 (0) (as (53.3)) <0.01 (as (53.3)) <0.026 (as (53.3)) <0.01 (as (53.3)) <0.026 (as (53.3)) <0.01 (as (53.3)) <0.01 (as (53.3)) <0.026 (as (53.3)) <0.026 (as (53.3)) <0.026 (as (53.3)) <0.026 (as (53.3)) <0.02 (as (53.3)) <0.024 (as (53.3)) <0.01 (as (53.3)) <0.01 (as (53.3)) <0.01 (as (53.3)) <0.01 (as (53.3)) <0.02 (as (53.3)) <0.02 (as (53.3)) <0.02 (as (53.3)) <0.01 (as (53.3)) <		Moderate	48 (37.5)	2 (13.3)	
Question 9 Moderate High 46 (35.9) 13 (86.7) Question 9 Low 2 (1.6) 0 (0) 0.26 Moderate 31 (24.2) 1 (6.7) 14 (93.3) 0 Question 10 Low 2 (1.6) 0 (0) 0.24 High 95 (74.2) 14 (93.3) 0 Question 10 Low 28 (29.7) 1 (6.7) 1 (6.7) High 88 (68.8) 14 (93.3) 0 Question 11 Low 38 (29.7) 0 (0) <0.01					
Question 9 High Low 2 (1.6) 0 (0) 0.26 Moderate High 31 (24.2) 1 (6.7) 0.26 High 95 (74.2) 14 (93.3) 0.00 Question 10 Low 2 (1.6) 0 (0) 0.24 Moderate 38 (29.7) 1 (6.7) 1 (6.7) High 88 (68.8) 14 (93.3) 0.00 Question 11 Low 38 (29.7) 0 (0) <0.01	Question 8				< 0.01
Question 9 Low Moderate Moderate and ST (24.2) 0 (0) (0) (0) (0.26) Question 10 Low (2 (1.6) (0) (0) (0) (0.24) Question 10 Low (2 (1.6) (0) (0) (0) (0.24) Moderate (10, 10) (10, 10) (10, 10) (10, 10) 38 (29.7) (1 (6.7)					
Question 10 Moderate High 95 (74.2) 14 (93.3) 0.00 0.24 Question 10 Low 2 (1.6) 0 (0) 0.24 Moderate 38 (29.7) 1 (6.7) 1 (6.7) High 88 (68.8) 14 (93.3) 0.00 Question 11 Low 38 (29.7) 0 (0) <0.01		-			
Question 10 Low 2 (1.6) 0 (0) 0.24 Moderate 38 (29.7) 1 (6.7) 0.24 High 88 (68.8) 14 (93.3) 0.00 Question 11 Low 38 (29.7) 0 (0) <0.01	Question 9				0.26
Question 10 Low 2 (1.6) 0 (0) 0.24 Moderate 38 (29.7) 1 (6.7) 1 (6.7) High 88 (68.8) 14 (93.3) Question 11 Low 38 (29.7) 0 (0) <0.01			, ,		
Question 11 Moderate High 88 (68.8) 14 (93.3) Question 11 Low 38 (29.7) 0 (0) <0.01	Ougstion 10	-			0.24
Question 11 Low 38 (29.7) 0 (0) < 0.01	Question 10		` '	, ,	0.24
Question 11 Low 38 (29.7) 0 (0) <0.01 Moderate 59 (46.1) 6 (40) 6 (40) High 31 (24.2) 9 (60) Question 12 Low 9 (7) 0 (0) 0.02 Moderate 66 (51.6) 3 (20) 14 12 (80) Question 13 Low 55 (43) 6 (40) 0.12 Moderate 61 (47.7) 5 (33.3) 14 12 (9.4) 4 (26.7) Question 14 Low 10 (7.8) 0 (0) 0.01 0.01 Moderate 68 (53.1) 3 (20) 12 (80) 0.01 0.01 Question 15 Low 37 (28.9) 0 (0) <0.01					
Moderate 59 (46.1) 6 (40) High 31 (24.2) 9 (60) Question 12 Low 9 (7) 0 (0) 0.02 Moderate 66 (51.6) 3 (20) 1 High 53 (41.4) 12 (80) 12 (80) Question 13 Low 55 (43) 6 (40) 0.12 Moderate 61 (47.7) 5 (33.3) 1 High 12 (9.4) 4 (26.7) 0 Question 14 Low 10 (7.8) 0 (0) 0.01 Moderate 68 (53.1) 3 (20) 1 High 50 (39.1) 12 (80) 0 Question 15 Low 37 (28.9) 0 (0) <0.01	Question 11	-			< 0.01
Question 12 High 31 (24.2) 9 (60) Question 12 Low 9 (7) 0 (0) 0.02 Moderate 66 (51.6) 3 (20) 12 High 53 (41.4) 12 (80) 12 (80) Question 13 Low 55 (43) 6 (40) 0.12 Moderate 61 (47.7) 5 (33.3) 14 12 (9.4) 4 (26.7) Question 14 Low 10 (7.8) 0 (0) 0.01 0.01 Moderate 68 (53.1) 3 (20) 0 0 0.01 Moderate 62 (48.4) 6 (40) 0 0 0.01 Question 15 Low 15 (11.7) 0 (0) 0.02 0.02 Question 16 Low 15 (11.7) 0 (0) 0.00 0.02 Question 17 Low 28 (21.9) 1 (6.7)	Question 11				₹0.01
Question 12 Low 9 (7) 0 (0) 0.02 Moderate High 66 (51.6) 3 (20) 0.02 Question 13 Low 55 (43) 6 (40) 0.12 Moderate G1 (47.7) 5 (33.3) 14 4 (26.7) 0.01 Question 14 Low 10 (7.8) 0 (0) 0.01 Moderate G8 (53.1) 3 (20) 14 12 (80) 0.01 Question 15 Low 37 (28.9) 0 (0) <0.01					
Question 13 Low 55 (43) 6 (40) 0.12 Question 13 Low 55 (43) 6 (40) 0.12 Moderate 61 (47.7) 5 (33.3) 1 High 12 (94) 4 (26.7) 0.01 Question 14 Low 10 (7.8) 0 (0) 0.01 Moderate 68 (53.1) 3 (20) 12 (80) 0.01 Question 15 Low 37 (28.9) 0 (0) <0.01	Ouestion 12	-			0.02
Question 13 Low Moderate Moderate G1 (47.7) 5 (33.3) 0.12 Moderate High 12 (9.4) 4 (26.7) 0.01 Question 14 Low 10 (7.8) 0 (0) 0.01 Moderate 68 (53.1) 3 (20) 12 (80) Question 15 Low 37 (28.9) 0 (0) <0.01	C				
Moderate 61 (47.7) 5 (33.3) High 12 (9.4) 4 (26.7) Question 14 Low 10 (7.8) 0 (0) 0.01 Moderate 68 (53.1) 3 (20) 12 (80) Question 15 Low 37 (28.9) 0 (0) <0.01		High	53 (41.4)	12 (80)	
Question 14 High 12 (9.4) 4 (26.7) Question 14 Low 10 (7.8) 0 (0) 0.01 Moderate 68 (53.1) 3 (20) 0 High 50 (39.1) 12 (80) Question 15 Low 37 (28.9) 0 (0) <0.01	Question 13	Low	55 (43)	6 (40)	0.12
Question 14 Low 10 (7.8) 0 (0) 0.01 Moderate High 68 (53.1) 3 (20) 3 (20) High 50 (39.1) 12 (80) 20.01 Question 15 Low 37 (28.9) 0 (0) <0.01		Moderate	61 (47.7)	5 (33.3)	
Question 15 Moderate High 68 (53.1) 3 (20) 37 (28.9) 0 (0) < 0.01		High	12 (9.4)	4 (26.7)	
Question 15 High 50 (39.1) 12 (80) Question 16 Low 37 (28.9) 0 (0) <0.01	Question 14				0.01
Question 15 Low Moderate Moderate High 37 (28.9) 0 (0) <0.01 Question 16 High 29 (22.7) 9 (60) 0.02 Question 16 Low 15 (11.7) 0 (0) 0.02 Moderate 59 (46.1) 3 (20) 12 (80) Question 17 Low 28 (21.9) 1 (6.7) <0.01					
Moderate 62 (48.4) 6 (40) High 29 (22.7) 9 (60) Question 16 Low 15 (11.7) 0 (0) 0.02 Moderate 59 (46.1) 3 (20) 12 (80) Question 17 Low 28 (21.9) 1 (6.7) <0.01	0 .: 45				0.04
Question 16 High 29 (22.7) 9 (60) Question 16 Low 15 (11.7) 0 (0) 0.02 Moderate 59 (46.1) 3 (20) 0 High 54 (42.2) 12 (80) 0 Question 17 Low 28 (21.9) 1 (6.7) <0.01	Question 15				< 0.01
Question 16 Low Moderate Moderate High 15 (11.7) 0 (0) 0.02 (0) Moderate High 59 (46.1) 3 (20)					
Question 17 Low 28 (21.9) 1 (6.7) < 0.01	Ouestion 16	-			0.02
Question 17 High 54 (42.2) 12 (80) Question 17 Low 28 (21.9) 1 (6.7) <0.01	Question 16				0.02
Question 17 Low 28 (21.9) 1 (6.7) <0.01 Moderate 69 (53.9) 4 (26.7)				, ,	
Moderate 69 (53.9) 4 (26.7) High 31 (24.2) 10 (66.7) Question 18 Low 55 (43) 1 (6.7) <0.01	Ouestion 17				< 0.01
Question 18 High 31 (24.2) 10 (66.7) Question 18 Low 55 (43) 1 (6.7) <0.01	C				
Question 18 Low 55 (43) 1 (6.7) <0.01					
Question 19 High 14 (10.9) 5 (33.3) Question 19 Low 6 (4.7) 1 (6.7) 0.18 Moderate 48 (37.5) 2 (13.3) High 74 (57.8) 12 (80) Question 20 Low 3 (2.3) 0 (0) 0.04 Moderate 35 (27.3) 0 (0) 0.04 High 90 (70.3) 15 (100) 0.08 Moderate 41 (31) 0 (0) 0.08 High 83 (64.8) 14 (93.3) Question 22 Low 3 (2.3) 0 (0) 0.05 Moderate 34 (26.6) 0 (0) 0.05	Question 18	-			< 0.01
Question 19 Low Moderate Moderate High 6 (4.7) 1 (6.7) 0.18 Moderate High 48 (37.5) 2 (13.3) 2 (13.3) 2 (13.3) 2 (13.3) 2 (13.3) 2 (13.3) 2 (13.3) 2 (13.3) 2 (13.2) 2 (13.2) 2 (13.2) 2 (13.2) 2 (13.2) 2 (13.2) 2 (13.2) 3 (10.2		Moderate	59 (46.1)	9 (60)	
Moderate High 48 (37.5) 2 (13.3) High 74 (57.8) 12 (80) Question 20 Low 3 (2.3) 0 (0) 0.04 Moderate 35 (27.3) 0 (0) 0.04 High 90 (70.3) 15 (100) 0.08 Question 21 Low 4 (3.1) 0 (0) 0.08 Moderate 41 (32) 1 (6.7) High 83 (64.8) 14 (93.3) Question 22 Low 3 (2.3) 0 (0) 0.05 Moderate 34 (26.6) 0 (0)		High	14 (10.9)	5 (33.3)	
Question 20 High 74 (57.8) 12 (80) Question 20 Low 3 (2.3) 0 (0) 0.04 Moderate 35 (27.3) 0 (0) 0.04 High 90 (70.3) 15 (100) 0.05 Question 21 Low 4 (3.1) 0 (0) 0.08 Moderate 41 (32) 1 (6.7) High 83 (64.8) 14 (93.3) Question 22 Low 3 (2.3) 0 (0) 0.05 Moderate 34 (26.6) 0 (0)	Question 19				0.18
Question 20 Low 3 (2.3) 0 (0) 0.04 Moderate 35 (27.3) 0 (0) 0.04 High 90 (70.3) 15 (100) 0.06 Question 21 Low 4 (3.1) 0 (0) 0.08 Moderate 41 (32) 1 (6.7) High 83 (64.8) 14 (93.3) Question 22 Low 3 (2.3) 0 (0) 0.05 Moderate 34 (26.6) 0 (0)				, ,	
Moderate High 35 (27.3) (0 (0) (0) (0) (0) (0) Question 21 Low (4 (3.1) (0 (0) (0) (0) (0) Moderate High (36.8) (64.8) (1 (67.) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1					
Question 21 High Moderate Moderate High Moderate Moderate Moderate High Moderate Moderate Moderate High Moderate	Question 20				0.04
Question 21 Low 4 (3.1) 0 (0) 0.08 Moderate 41 (32) 1 (6.7) High 83 (64.8) 14 (93.3) Question 22 Low 3 (2.3) 0 (0) 0.05 Moderate 34 (26.6) 0 (0)					
Moderate 41 (32) 1 (6.7) High 83 (64.8) 14 (93.3) Question 22 Low 3 (2.3) 0 (0) 0.05 Moderate 34 (26.6) 0 (0)	Ougstie = 31	-			0.00
Question 22 High Low 3 (64.8) 14 (93.3) Noderate 34 (26.6) 0 (0) 0.05	Question 21				0.08
Question 22 Low 3 (2.3) 0 (0) 0.05 Moderate 34 (26.6) 0 (0)					
Moderate 34 (26.6) 0 (0)	Question 22	-			0.05
, , ,	Question 22				0.03
High 91 (71.1) 15 (100)				, ,	

Scale scores: low = 1-4, moderate = 5-7, high > 7.

items and the suitability of factor analysis in this dataset. Likewise, Bartlett's Test of Sphericity showed significance ($\chi^2=1373.617$, p<0.001), which confirmed that correlations between variables warrant the use of a factor model.

The scree plot (Fig. 1) included the values obtained for each component, showing a significant reduction after Factor 6. This turning point supports the selection of a six-factor structure as the most suitable for describing the underlying dimensions of the questionnaire. Each factor

represents a specific dimension of the phenomenon tested. Factor 1 stood out with high factor loadings in the questions related to general perceptions and technical competences of clinical rotation (P13, P21 and P22, with loadings >0.7). Factor 2 encompassed items associated with practical skills and specific technical competences (P2, P3 and P9, with loadings >0.6). The remaining factors provide a broader perspective. Factor 3 is associated with the applicability of knowledge; Factor 4 with interpersonal skills and teamwork; Factor 5 with confidence and autonomy in decision-making; and Factor 6 with motivation and satisfaction with training. This structure provides a comprehensive understanding of the latent components investigated.

The consistency of the model was also confirmed by communalities, which ranged from 0.457 to 0.865, with most variables exceeding the 0.6 threshold, which indicates that they are adequately represented by the factors identified.

Discussion

To the best of our knowledge, this is the first study to assess the level of knowledge, perception and predisposition of hospital pharmacy residents in Spain regarding the MAPEX project. The results obtained provide a comprehensive perspective of the current impact of this strategy on pharmacy residents.

Completion of outpatient pharmacy practice rotation was significantly associated with a higher level of knowledge and adoption of the method and initiatives developed, which supports its role as a key component in PR training and education. This finding is consistent with previous studies underscoring the relevance of direct clinical experiences in consolidating technical skills and improving the implementation of innovative healthcare models. However, the variability observed among residents suggests a lack of homogeneity regarding their knowledge of MAPEX. Discrepancies could stem from structural and organizational differences across HP departments. These differences may also stem from variability in the training of HP supervisors responsible for conveying the core instructional components of pharmacy practice rotations.

Incorporating standardized practice rotation plans into the future national PR rotation plan would help overcome these limitations and promote greater uniformity in education and training. In this sense, international initiatives such as the ASHP Practice Advancement Initiative 2030 promote the integration of structured clinical experiences as a strategy to improve training among hospital pharmacists in early training stages.⁴ This approach should be adopted in Spain to enhance the impact of MAPEX.

With regard to specific initiatives, although respondents considered motivational interviewing relevant, they rarely apply this strategy. This unbalance illustrates a gap between theory and practice. The observed imbalance reveals a gap between theory and practice, likely attributable to inadequate communication training during PR and aligned with the ongoing transition from a drug-centered approach toward a patient-centered model of care. Pharmacy residency plans should incorporate specific modules on motivational interviewing, such as those implemented in multidimensional models of care, as these have been shown to improve treatment adherence and health outcomes.¹⁷

The observed association between greater knowledge of MAPEX and an increased willingness to apply it in future practice underscores the need to integrate targeted content from the most recent initiatives into PR programs. This recommendation is consistent with the principle of continuous learning, widely recognized as essential for maintaining professional competence in evolving healthcare environments. ^{18,19} Moreover, the progressive implementation of the QPEX certification standard in Spanish hospitals may serve as an additional incentive to promote the adoption of quality-oriented practices, as has been reported in comparable experiences across other European countries. ²⁰

The establishment of MAPEX as a standard of outpatient care has the potential to improve health outcomes, foster multidisciplinary

^{*} p calculated by the Chi-square test or Fisher's exact test, as appropriate.

M. Alfonsín Lara, V. Áreas del Águila, E. Contreras Macías et al.

Farmacia Hospitalaria xxx (xxxx) 1–7




Figure 1. Scree plot of the factorial analysis performed.

collaboration, and optimize resource utilization, in line with the vision of hospitals of the future.²¹ Nevertheless, to ensure its successful integration, it is crucial to address identified barriers, dispel misconceptions and false beliefs, and reduce variability in training access and the lack of standardization.²² Additionally, the development of technologies enabling the implementation of the CMO model could expedite its adoption, in line with other healthcare settings.²³

Our study has some limitations. Firstly, the use of a novel, anonymous, self-administered questionnaire may have produced social or professional-desirability bias or interpretation bias by participants, potentially affecting the accuracy of responses. Secondly, data collection was conducted exclusively online, which may have limited participation among less motivated residents. The cross-sectional design of the study precludes the establishment of causal relationships between the variables analyzed, restricting interpretation to the identification of significant associations. Finally, although broad sampling was attempted, the final sample size may not fully reflect the diversity of training and organizational contexts of PR programs across Spain, particularly in regions with lower representation. Despite these limitations, the study also demonstrated several methodological strengths. The structural validation of the questionnaire ensured internal consistency and allowed for the identification of key dimensions related to the knowledge, perception, and implementation of MAPEX. This tool could be replicated in future research to monitor progress and assess long-term impact, thereby contributing to a broader understanding of both educational and clinical needs.

In conclusion, this study identified variable levels of knowledge, generally favorable perceptions, and a high willingness among FIR residents to participate in the future implementation of MAPEX initiatives. These findings suggest promising prospects for the expansion and sustainability of MAPEX as a guiding framework for ambulatory care in specialized settings in Spain over the coming years.

Contribution to the scientific literature

This study represents a significant contribution to the field of Hospital Pharmacy as it is the first to assess the level of knowledge, perceptions, and willingness of hospital pharmacy residents in Spain with respect to the MAPEX project (Strategic Outpatient Pharmaceutical care Plan) of the Spanish Society of Hospital Pharmacy. The findings underscore the value of outpatient clinic rotations in consolidating key competencies, as well as the need to standardize and expand training in pharmaceutical care within the specialty program. Furthermore, the

results reflect a favorable perception of the initiatives developed under MAPEX, particularly in areas such as multidisciplinary integration and anticipatory patient care. Overall, this research provides evidence supporting the relevance of the initiative in both training and clinical practice, highlighting its potential to enhance the quality of pharmaceutical care. The data generated may inform strategic planning and the implementation of harmonized educational policies on MAPEX, thereby contributing to the advancement of pharmaceutical practice and the long-term sustainability of healthcare delivery.

Ethic considerations

The study protocol was reviewed and approved by the Ethics Committee Sevilla Sur (SICEIA-2024-001533).

CRediT authorship contribution statement

María Alfonsín Lara: Writing – review & editing, Visualization, Validation, Methodology. Vera Áreas del Águila: Writing – review & editing, Visualization, Validation, Methodology, Investigation, Conceptualization. Enrique Contreras Macías: Writing – review & editing, Writing – original draft, Validation, Formal analysis, Data curation. Almudena Mancebo González: Writing – review & editing, Validation, Investigation, Data curation, Conceptualization. Beatriz Martínez Castro: Writing – review & editing, Visualization, Validation, Methodology, Investigation. Covadonga Pérez Menéndez-Conde: Writing – review & editing, Visualization, Validation, Project administration, Investigation, Conceptualization. Patricia Sanmartín Fenollera: Writing – review & editing, Visualization, Validation, Investigation. Ramón Morillo-Verdugo: Writing – review & editing, Writing – original draft, Visualization, Validation, Supervision, Project administration, Investigation, Conceptualization.

Authorship

All authors contributed equally to the inception and design of the study. Ramón Morillo-Verdugo prepared the manuscript. All authors reviewed and approved the final version of the manuscript for submission.

Funding

This study did not receive any funding.

M. Alfonsín Lara, V. Áreas del Águila, E. Contreras Macías et al.

Farmacia Hospitalaria xxx (xxxx) 1-7

Conflict of interest

The authors declare no conflicts of interest associated with this publication.

Acknowledgements

Thanks to all study participants. Thanks to Dr. Manuel Vélez Díaz-Pallares for his unvaluable collaboration in the development of the project.

References

- 1. Ageing | Naciones Unidas. [accessed 04 Dic 2024]. Available from: https://www.un.org/en/global-issues/ageing.
- Maani N, Van Schalkwyk MC, Petticrew M, Ralston R, Collin J. The new WHO Foundation-global health deserves better. *BMJ Glob Health*. 2021; 6(2):e004950. doi:10.1136/bmjgh-2021-004950.
- 3. Alianzas estratégicas en el entorno hospitalario. Guía Práctica para su Implantación. [accessed 04 Dic 2024]. Available from: https://calidadasistencial.es/wp-content/uploads/2019/02/Amphos-2015-Alianzas-estrat%C3%A9gicas-entorno-sanitario.pdf.
- ASHP Practice Advancement Initiative 2030: new recommendations for advancing pharmacy practice in health systems. *Am J Health-Syst Pharm*. 2020;77(2):113–121. doi:10.1093/ajhp/zxz271.
- El proyecto MAPEX. Documentación. [accessed 04 Dic 2024]. Available from: https://www.sefh.es/mapex/documentacion.php.
- Morillo-Verdugo R, Aguilar Pérez T, Gimeno-Gracia M, Rodríguez-González C. Robustillo-Cortes MLA; representing the project research team belonging to the HIV Pharmaceutical Care group of the (SEFH). Simplification and Multidimensional Adaptation of the Stratification Tool for Pharmaceutical Care in People Living With HIV. *Ann Pharmacother*. 2023 Feb;57(2):163–174. doi:10.1177/10600280221096759. PMID: 35707861. Epub 2022 Jun 15.
- Documentos de apoyo metodológico para la telefarmacia. [accessed 04 Dic 2024]. Available from: https://www.sefh.es/mapex/cmooportunidad.php.
- 8. Morillo-Verdugo R, Calleja-Hernández MÁ, de Las Aguas Robustillo-Cortés M. A new pharmaceutical care concept: more capable, motivated, and timely. *Hosp Pharm.* 2019;54(6):348–350. doi:10.1177/0018578719867657.
- Calleja-Hernández MA, Morillo-Verdugo R. El modelo CMO en consultas externas de Farmacia Hospitalaria. [accessed 04/12/24]. Available from: https://www.sefh.es/sefhpdfs/Libro_CMO.pdf.
- Morillo-Verdugo R, Calvin Lamas M, Delgado Latorre ATJ, Ferrando Piqueres R, Fernández-Llamazares CM, Negro Vega E, et al. Desarrollo de la norma Q-PEX de certificación de calidad de la atención farmacéutica a pacientes externos de los servicios de Farmacia. *J Healthc Qual Res.* 2021; 36(6):324–332. doi:10.1016/j.jhqr.2021.03.010.
- 11. Morillo-Verdugo R, Vicente-Escrig E, Murillo Izquierdo M, Ibarra Barrueta O, Taberner Bonastre P, Fernández-Llamazares CM. Análisis de

- la evolución de la atención farmacéutica al paciente externo en los servicios de farmacia hospitalaria en España tras la puesta en marcha y desarrollo de la iniciativa MAPEX. *J Healthc Qual Res.*. 2024;39(2):65–79. doi:10.1016/j.jhqr.2023.11.002.
- Vicente-Escrig E, Taberner Bonastre P, Ibarra Barrueta O, Murillo Izquierdo M, Fernández-Llamazares CM, Morillo-Verdugo R. Analysis 2016–2021 of the development of the MAPEX outpatient pharmaceutical care Project by regions in Spain. *Farm Hosp.* 2023. doi:10.1016/j. farma.2023.08.007. S1130-6343(23)00349-5.
- 13. Programa Nacional de la Especialidad en Farmacia Hospitalaria.

 Documentación. [accessed 12 Dic 2024]. Available from: https://www.sanidad.gob.es/areas/profesionesSanitarias/formacionEspecializada/consejoNacional/docs/Farmacia_Hospitalaria.pdf.
- 14. Gimeno-Jordá MJ, Giménez-Poderos T, Negro-Vega E, Fernández-de Gamarra E, Sanmartín-Fenollera P, Lozano-Blázquez A, et al. Evaluation of specialized training in hospital pharmacy. *Farm Hosp.* 2020;44(5): 198–211. doi:10.7399/fh.11414. PMID: 32853125.
- Cooper JB, Scotti A, Carr ML. Implementing medicare education for medication access: a review of the literature using the RE-AIM framework. *Res Social Adm Pharm*. 2023;19(1):16–27. doi:10.1016/j.sapharm. 2022.08.013.
- 16. Murry LT, Witry MJ, Urmie J. Medicare part D plan-selection experience: qualitative findings from a national cross-sectional survey. *Explor Res Clin Soc Pharm.* 2023;9:100219. doi:10.1016/j.rcsop.2022.100219.
- 17. Sánchez-Yáñez E, Huertas-Fernández MJ, Robustillo-Cortes MA, Ramos-Guerrero R, Fernández-Espínola S, Diaz-Acedo R, et al. Application of CMO (capacity, motivation, and opportunity) methodology in pharmaceutical care to optimize the pharmacotherapy in older people living with HIV. DISPIMDINAC project. *Rev Esp Quimioter*. 2023;36(6): 584–591. doi:10.37201/req/021.2023.
- 18. Frenk J, Chen L, Bhutta ZA, Cohen J, Crisp N, Evans T, et al. Health professionals for a new century: transforming education to strengthen health systems in an interdependent world. *Lancet*. 2010;376(9756): 1923–1958. doi:10.1016/S0140-6736(10)61854-5.
- Cordero-Cruz AM, Fernández de Gamarra-Martínez E, Florencio M, González-Haba E, Marcos JA, Molina García T, et al. Tackling the future in hospital pharmacy: training as a pillar of success. *Farm Hosp.* 2024;48 (Suppl 1):S45–S51. doi:10.1016/j.farma.2024.05.012.
- Ţăran AM, Mustea L, Vătavu S, Lobonţ OR, Luca MM. Challenges and drawbacks of the EU medical system generated by the COVID-19 pandemic in the field of health systems' digitalization. *Int J Environ Res Public Health*. 2022;19(9):4950. doi:10.3390/ijerph19094950.
- 21. Gómez Huelgas R, Díez Manglano J, Carretero Gómez J, Barba R, Corbella X, García Alegría J, et al. The hospital of the future in 10 points. *Rev Clin Esp (Barc)*. 2020;220(7):444–449. doi:10.1016/j.rce.2020.04.009.
- 22. Adopción y puesta en valor del modelo CMO. [accessed 04 Dic 2024]. Available from: https://www.sefh.es/mapex/humanizacion.php.
- 23. What is patient-centered care? [accessed 22 Mar 2024]. Available from: https://catalyst.nejm.org/doi/full/10.1056/CAT.17.0559.